ResearchMoz

LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 42

GlobalDatas pharmaceuticals report, LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020 provides LY2189265 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of LY2189265 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of LY2189265 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for LY2189265 in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 LY2189265 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase II 25
7.3.2 Phase III 25
7.4 Factors Affecting Sales of LY2189265 26
7.4.1 Once Weekly Dosage 26
7.4.2 Competition from Januvia 26
7.4.3 Approval of Bydureon 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 27
7.6.1 Target Patient Pool for LY2189265 27
7.6.2 Dosing 27
7.6.3 Market Penetration 28
7.6.4 Annual Cost of Therapy 29
7.6.5 Sales Projections of LY2189265 30

8 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 39
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Number of patients approved to take the drug 40
8.3.5 Net Penetration of Drug 41
8.3.6 Net Annual Dosing 41
8.3.7 Annual Cost of Therapy 41
8.4 Drug Sales Estimates Model 41
8.5 Contact Us 41
8.6 Disclaimer 41
8.7 Sources 42

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of LY2189265 26
Table 10: Estimated Annual Cost of Therapy of LY189265, 2014 29
Table 11: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Table 12: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Table 13: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Table 14: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Table 15: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Table 16: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20142020 35
Table 17: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Table 18: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
Figure 12: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Figure 13: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Figure 14: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Figure 15: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Figure 16: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Figure 17: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 35
Figure 18: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Figure 19: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37
Figure 20: LY2189265, Type 2 Diabetes, Global, Sales Distribution (%), 2020 38
Figure 21: Patients Approved for the Drug 40

Upcoming Reports:

Greece: market of glaziers and grafting putty, resin cements, painters fillings
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the glaziers and grafting putty, resin cements, painters fillings market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the glaziers and grafting putty, resin cements, painters fillings market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for...
High Temperature Insulation (HTI) Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Some of the major factors driving HTI market are the increasing demand of energy and power from industries, growing awareness about the environment and depletion of traditional sources of energy. The major benefits offered by HTI products are sustainability at high temperatures and high compressive strength. High temperature insulation products are widely used in industrial applications, fire protection and emission control applications. Some of the industries where HTI products are used widely are petrochemicals, refractory, metallurgy, glass, cement, aluminum and others....
Metal And Ceramic Injection Molding Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Metal injection molding (MIM) and ceramic injection molding (CIM) are advanced net shape processing technologies used for the manufacture of complex, high-volume components. Together, these molding technologies are known as powder injection molding (PIM). The technology is gaining importance as new components are being designed that require high mechanical strength while being small in size. Additionally, industries such as automotive and aerospace are looking at reducing production costs, which can be achieved using metal and ceramic injection molding processes. The low cost complex...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
China to Invest in UKs Infrastructure Industry
Oct 28, 2014  
As per industry reports, it is expected that in the year 2015, the UK infrastructure will derive benefits from 105 billion pounds of Chinese money. This will involve a host of Chinese machinery suppliers, contractors, and materials producers. The UK government will be spending about half of 225 billion pounds on its own infrastructure. The investors from China will be investing...